The article reports that pharmaceutical firm Roche has presented data before the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) which confirms the efficacy of the ocrelizumab drug as a treatment for primary progressive multiple sclerosis (PPMS).